People · Operator
Named in public records as an officer, director or promoter · active 2018–2022 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Camp4 Therapeutics Corp | — | Biotechnology | Series D+ | $179.6M | $2.2B | 2018 |
JOSH MANDEL-BREHM at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside JOSH MANDEL-BREHM on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Amir Nashat | 1 | 14 |
| Michael Higgins | 1 | 9 |
| Andrew J. Schwab | 1 | 7 |
| Jorge Conde | 1 | 4 |
| Shaan Gandhi | 1 | 4 |
| Paula Ragan | 1 | 3 |
| Andy Schwab | 1 | 2 |
| ANN BARBIER | 1 | 2 |
| Shaan I Gandhi | 1 | 2 |
| JAMES J. BOYLAN | 1 | 1 |
| RAVI THADHANI | 1 | 1 |
| STEVE HOLTZMAN | 1 | 1 |
| RAVI I. THADHANI | 1 | 1 |
| RICHARD YOUNG | 1 | 1 |
| CALEB MOORE | 1 | 1 |
| ALFICA SEHGAL | 1 | 1 |
| MICHELLE GATES | 1 | 1 |
| KELLY GOLD | 1 | 1 |
| DAVID BUMCROT | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.